Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin–Unresponsive Non–Muscle Invasive Bladder Cancer
Taylor J, Kamat A, Annapureddy D, Khene Z, Howard J, Tan W, McElree I, Facundo D, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, Woldu S, Lotan Y, O'Donnell M. Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin–Unresponsive Non–Muscle Invasive Bladder Cancer. European Urology Oncology 2024, 8: 469-476. PMID: 39694798, DOI: 10.1016/j.euo.2024.12.005.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicAdministration, IntravesicalAgedAntineoplastic Combined Chemotherapy ProtocolsBCG VaccineDeoxycytidineDocetaxelFemaleGemcitabineHumansMaleMiddle AgedNeoplasm InvasivenessNon-Muscle Invasive Bladder NeoplasmsRetrospective StudiesTreatment OutcomeUrinary Bladder NeoplasmsConceptsNon-muscle-invasive bladder cancerBCG-unresponsive NMIBCBacillus Calmette-GuerinOncological outcomesBladder cancerIntravesical gemcitabineNon-muscle invasive bladder cancerBacillus Calmette-Guerin treatmentHazard ratioBacillus Calmette-Guerin therapyBacillus Calmette-Guerin groupCompare oncologic outcomesInvasive bladder cancerCox proportional hazard ratiosKaplan-Meier methodNoninvasive bladder cancerRates of PFSProportional hazard ratiosAssociated with lower ratesFood and Drug Administration guidelinesBCG-unresponsiveDrug Administration guidelinesGemcitabine-docetaxelBCG therapyProgression-Free
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply